Home
    Disclaimer
    DMXE molecular structure

    DMXE Stats & Data

    3d-mxe Warm-k 3-me-2'-oxo-pce
    NPS DataHub
    MW231.34
    FormulaC15H21NO
    IUPAC2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one
    SMILESCCNC1(CCCCC1=O)c1cccc(C)c1
    InChIKeyWIMLPRYZJQNQLE-UHFFFAOYSA-N
    Arylcyclohexylamines; 2021/6. Von Arylcyclohexylamin abgeleitete Verbindungen; 2022/6. Von Arylcyclohexylamin abgeleitete Verbindungen
    Psychoactive Class Dissociative
    Half-Life Unknown in humans; user reports suggest a duration on the order of hours (commonly 4–7 h total depending on ROA), but no validated PK data are available; treat estimates such as 3–6 h as speculative.

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist (noncompetitive)

    History & Culture

    DMXE emerged as a novel research chemical around October 2020, when it first appeared on online designer drug markets. The compound is structurally derived from methoxetamine (MXE), with the 3-methoxy substituent replaced by a methyl group—hence its alternative designation as "3D-MXE" (3-desmethoxy-MXE). It was first definitively identified by a forensic laboratory in Denmark in February 2021, marking its formal entry into scientific documentation of novel psychoactive substances. The compound appeared during a period of continued innovation in the arylcyclohexylamine research chemical space, following patterns established by earlier designer dissociatives. Its emergence reflects ongoing efforts within clandestine chemistry to develop structural analogues of controlled or unavailable substances like MXE.

    Effect Profile

    Curated + 14 Reports
    Dissociative 5.7

    Strong dissociative depth and motor impairment with moderate mania, low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    6
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Insufflated
    4-15 minutes
    15-30 minutes
    30 minutes - 1.5 hours
    2-3 hours
    1-2 hours
    Oral
    19-40 minutes
    30 minutes - 1.0 hours
    30 minutes - 1.5 hours
    2-3 hours
    1-2 hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; user reports suggest a duration on the order of hours (commonly 4–7 h total depending on ROA), but no validated PK data are available; treat estimates such as 3–6 h as speculative.
    Addiction Potential
    Moderate psychological dependence risk similar to other arylcyclohexylamine dissociatives; binge-style redosing and frequent use increase risk.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~28d

    Acute tolerance rises within a session and across days; many users report unpredictability and diminished effects with frequent use. Long washouts (≥4 weeks) are commonly used to restore baseline response. Estimates are anecdotal and inferred from MXE/ketamine patterns and community reports on DMXE.

    Cross-Tolerances

    ketamine
    70% ●○○
    methoxetamine (MXE)
    80% ●○○
    MXPr
    60% ●○○
    other arylcyclohexylamines
    50% ●○○

    Experience Report Analysis

    Erowid
    14 Reports
    2020–2024 Date Range
    14 With Age Data
    22 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 14 experience reports (14 Erowid)

    14 Reports
    22 Effects Detected
    9 Positive
    7 Adverse
    6 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 9

    Music Enhancement 78.6% 70%
    Stimulation 64.3% 70%
    Euphoria 57.1% 70%
    Empathy 57.1% 70%
    Color Enhancement 50.0% 70%
    Focus Enhancement 50.0% 70%
    Tactile Enhancement 42.9% 70%
    Body High 35.7% 70%
    Introspection 28.6% 70%

    Adverse Effects 7

    Anxiety 35.7% 70%
    Confusion 35.7% 70%
    Muscle Tension 21.4% 70%
    Sweating 21.4% 70%
    Motor Impairment 21.4% 70%
    Memory Suppression 21.4% 70%
    Nausea 21.4% 70%

    Real-World Dose Distribution

    62K Doses

    From 12 individual dose entries

    Insufflated (n=11)

    Median: 55.0mg 25th: 22.5mg 75th: 65.0mg 90th: 70.0mg
    mg/kg median: 0.716 mg/kg 75th: 0.942

    Form / Preparation

    Most common forms and preparations reported

    Harm Reduction

    drugs.wiki

    • Identity: DMXE = 3-Me-2′-oxo-PCE, also known as 3D‑MXE. This places it in the ketamine/PCx family with likely NMDA receptor antagonism; human pharmacokinetics remain poorly characterized. • Mislabeling risk: Drug checking services have found DMXE sold as MXE; do not assume a vendor or pellet label is accurate—use reagent/lab testing where available. • Combining CNS depressants (alcohol, GHB/GBL, opioids) with dissociatives markedly increases risks of loss of consciousness, aspiration and respiratory depression; if someone becomes unresponsive, place them in the recovery position and seek help. • Benzodiazepines and dissociatives potentiate each other’s sedation/ataxia and can lead to unexpected blackouts at high doses; treat as a caution-only combination. • Stimulant or serotonergic co-use (e.g., MDMA/SSRIs) can produce unpredictable effects (e.g., anxiety, blood-pressure elevation, or unusual mood shifts), and MXE analogs have specific MAOI/SSRI cautions—avoid such mixes or proceed only with expert-level caution. • Repeated/frequent dissociative use is linked to urinary tract (‘ketamine cystitis’) and biliary complications with ketamine; similar risks may generalize to analogs—watch for urinary urgency, pain or blood; take prolonged breaks and stop use if symptoms appear. • Expect marked motor impairment and poor situational awareness—clear hazards, stay seated/lying at higher doses, and never drive. General dissociative harm-reduction stresses environment control and moderation. • Intranasal use: crush finely; avoid shared/contaminated implements; rinse with sterile saline before/after to reduce mucosal damage. • Potency and duration vary by batch and route; some users report prolonged residual dissociation after high cumulative dosing or all‑night redosing—resist the urge to ‘chase the hole’ and allow full plateaus to resolve before considering more. • The smell or color of product (e.g., tan/odorous powder, black/grey pellets) is not a quality guarantee and may reflect impurities or excipients; lab testing beats home ‘purification’ hacks.

    ← Back to DMXE